Clinical Trials Browser

Leukemia, Myeloid, Acute × venetoclax × 30 days × Clear all

NCT05554393 2026-04-22

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06672146 2026-04-22

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07320235 2026-04-22

IMAGINE

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04628026 2026-04-21

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05222984 2026-04-20

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05564390 2026-04-20

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03586609 2026-04-17

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04797767 2026-04-17

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Phase 1/2 Recruiting

Other hematologic neoplasmSarcoma

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT05554406 2026-04-17

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06317649 2026-04-17

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04140487 2026-04-16

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Phase 1/2 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT06782542 2026-04-16

OLUVENAZA

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02250937 2026-04-15

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04975919 2026-04-15

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT02392572 2026-04-14

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1/2 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05360160 2026-04-14

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03041688 2026-04-13

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04284787 2026-04-13

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Phase 2 Active not recruiting

60 enrolled 11 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05453903 2026-04-13

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05554419 2026-04-13

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05955261 2026-04-13

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Phase 2 Suspended

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06284486 2026-04-13

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06504459 2026-04-13

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT06514261 2026-04-13

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06651229 2026-04-13

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06802523 2026-04-13

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

Phase 1 Suspended

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06852222 2026-04-13

cAMeLot-2

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06954987 2026-04-13

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07153497 2026-04-13

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Phase 2 Not yet recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07437950 2026-04-13

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07469046 2026-04-13

VAH vs VA in Newly Diagnosed Elderly AML

Phase 3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03466294 2026-04-09

Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

Phase 2 Completed

42 enrolled 9 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07007312 2026-04-09

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07177079 2026-04-09

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04102020 2026-04-08

VIALE-M

Phase 3 Completed

112 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05442216 2026-04-08

TAGALONG

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06419634 2026-04-08

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06763341 2026-04-08

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Suspended

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04227847 2026-04-07

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07514832 2026-04-07

VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07514936 2026-04-07

Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07511062 2026-04-06

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

Phase 1 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04256317 2026-04-03

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Phase 2/3 Recruiting

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07374029 2026-04-03

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Phase 1 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07507825 2026-04-02

VHAG

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06660368 2026-04-01

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT06563804 2026-03-30

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

Phase 1/2 Terminated

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic